HOME >> BIOLOGY >> NEWS
Genome-wide mouse study yields link to human leukemia

s.

While it was Caligiuri's laboratory that designed the mouse model, it was Plass who supervised the methylation studies. He and his colleagues used a system called Restriction Landmark Genome Sequencing (RLGS) to compare methylation patterns among the three groups of mice a method of using enzymes and gel electrophoresis to map tiny bits of DNA on a grid. The stretches of DNA, referred to as fragments, show up as smudgy blobs on a test film. If a fragment is dark and definite, it is not methylated. If, on the other hand, it loses at least 30 percent of its intensity, it is regarded as methylated.

In the study, the research team tested 2447 fragments in each animal. They found anywhere from 45 to 209 (.8 percent to 8.5 percent) of the fragments methylated in the mice with cancer, but only one or two methylated fragments in the other mice.

"Interestingly, that same range of methylated fragments is exactly what we find in human leukemia, too," says Caligiuri, "so that gives added merit to our mouse model as an investigative tool."

Using data from the methylation studies, Caligiuri and Plass were able to identify a particular stretch of DNA, called Id4, as a tumor suppressor gene.

Tumor suppressor genes help control cancer by identifying and getting rid of defective cells before they have a chance to mature and divide. When tumor suppressor genes lose that ability as they can if they are silenced through methylation or some other process, it gives cancer a chance to establish a foothold and spread.

Caligiuri says much more work needs to be done, but adds that the identification of Id4 as a likely tumor suppressor gene gives clinicians another possible target for intervention.

"We already have a drug, decitabine, that we know can reverse the effects of methylation," says Plass. "We are just beginning to figure out how it best works in humans, but simply knowing that we have a new target that may be meanin
'"/>

Contact: Michelle Gailiun
Gailiun.1@osu.edu
614-293-3737
Ohio State University
20-Feb-2005


Page: 1 2 3

Related biology news :

1. Genome-wide search unearths surprising clues for diabetes and triglycerides
2. OHSU turns mouse into factory for human liver cells
3. Virtual mouse brains now available online
4. New approaches to endometriosis treatment -- mouse experiments point the way
5. New mouse model closely mimics human cancers
6. Statin treatment improves spatial memory in mouse models of Alzheimers
7. Treatment extends survival in mouse model of spinal muscular atrophy
8. UCSF stem cell study reveals cells capability in mouse brain tissue repair
9. Mutant mouse provides insights into breast cancer
10. Mapping the mouse genome
11. MRSA vaccine shows promise in mouse study

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Genome wide mouse study yields link human leukemia

(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet ... specializing in clinical study management systems, has recently ... , further distinguishing iMedNet ... Research Organizations (CROs) and healthcare consultants.  Building on ... prospective customer referrals and numerous co-marketing opportunities), MedNet,s ...
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
(Date:3/3/2015)... March 3, 2015  Rosa & Co. LLC, a ... and simulation research, today announced it has two posters ... for Clinical Pharmacology and Therapeutics meeting in ... Logo - http://photos.prnewswire.com/prnh/20150302/179058LOGO   ... a poster describing a quantitative systems pharmacology approach for ...
(Date:3/3/2015)... 03, 2015 Genedata, a leading ... and life science research, today announced that Pfizer ... platform for use at Pfizer biopharma research and ... is supporting Pfizer’s global deployment and roll out ... for Therapeutic Innovation (CTI), and Pharmaceutical Sciences groups. ...
(Date:3/3/2015)... 03, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Gene Therapy - ... , Gene therapy technologies are ... and cell therapy with genetically modified vectors. Gene ... and various routes of administration as well as ...
(Date:3/3/2015)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of ... on protecting the microbiome, announced today that Jeffrey Riley ... 27th Annual ROTH Conference being held on March 8-11, 2015 ... Dana Point, CA. Mr. Riley is ... p.m. (Pacific Time). A live webcast of Synthetic ...
Breaking Biology Technology:Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
Cached News: